Author [reference] | Country | Type of study | Interferon regimen (duration in weeks) | Follow-up (range) in months | Sample size | Rate of HCC (n/n) | Significance |
---|---|---|---|---|---|---|---|
Mazzella, 1996 [184] | Italy | NRCT, P | 3 MU tiw (52) | 32 (12–71) | T 193 C 91 | T: 5/193 (2.6%) C: 9/91 (9.9%) | Significant |
Fattovich, 1997 [196] | Europe | NRCT, P | ≥ 200 MU | 60 (1–153) | T 193 C 136 | T: 7/193 (3.6%) C: 16/136 (11.8%) | Not significant |
Bruno, 1997 [45] | Italy | NRCT, P | 6 MU tiw (26) | 68 (60–84) | T 82 C 81 | T: 6/82 (7.3%) C: 14/81 (17.3%) | Not significant |
Serfaty, 1998 [197] | France | NRCT, P | 3 MU tiw (48) | 40 (6–72) | T 59 C 44 | T: 2/59 (3.4%) C: 9/44 (20.1%) | Significant |
IHCSG, 1998 [187] | Argentina, Germany, Italy, Saudi Arabia | NRCT, R | 9–30 MU/wk (3–30 months) | (36–250) | T 232 C 259 | T: 2/232 (0.9%) C: 48/259 (18.5%) | Significant |
Imai, 1998 [198] | Japan | NRCT, R | 480 MU (26) | 48 (3–65) | T 32 C 20 | T: 8/32 (25%) C: 7/20 (35%) | Significant |
Benvegnù, 1998 [188] | Italy | NRCT, P | 3–6 MU tiw (26–52) | 72 | T 75 C 77 | T: 4/75 (5.3%) C: 20/77 (26.0%) | Significant |
Valla, 1999 [199] | France | RCT | 3 MU TIW (48) | 40 (37–53) | T 47 C 52 | T: 5/47 (10.6%) C: 9/52 (17.3%) | Not significant |
Yoshida, 1999 [194] | Japan | NRCT, R | 480 MU (23) | 52 | T 230 C 107 | T: 33/230 (14.3%) C: 29/107 (27.1%) | NR |
Okanoue, 1999 [200] | Japan | NRCT, R | 3–10 MU qd or tiw (16–24) | 1–7 years | T 40 C 55 | T: 7/40 (17.5%) C: 22/55 (40.0%) | NR |
Nishiguchi, 1995/2001 [201,202] | Japan | RCT | 6 MU tiw (12–24) | 104 (31–110) | T 45 C 45 | T: 12/45 (26.7%) C: 33/45 (73.3%) | Significant |
Gramenzi, 2001 [203] | Italy | RCT, P | 741 MU | 72 | T 72 C 72 | T: 6/72 (8.3%) C: 19/72 (26.4%) | Significant |
Testino, 2002 [204] | Italy | RCT | 3 MU tiw (52) | 96.5 ± 18 | T 51 C 71 | T: 15.51 (29.4%) C: 24/71 (33.8%) | Not significant |